Digestive neuroendocrine neoplasms: A 2016 overview.

[1]  J. Strosberg,et al.  Gastroenteropancreatic Neuroendocrine Tumors , 2018, CA: a cancer journal for clinicians.

[2]  James C Yao,et al.  Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study , 2016, The Lancet.

[3]  M. Miederer,et al.  Surgical Treatment of NEN of Small Bowel: A Retrospective Analysis , 2016, World Journal of Surgery.

[4]  E. Krenning,et al.  ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum , 2016, Neuroendocrinology.

[5]  P. Ruszniewski,et al.  Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study , 2016, Endocrine-related cancer.

[6]  C. Schade-Brittinger,et al.  Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival , 2016, Neuroendocrinology.

[7]  R. Jensen,et al.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors , 2016, Neuroendocrinology.

[8]  V. Ambrosini,et al.  Prognostic Value of 68Ga-DOTANOC PET/CT SUVmax in Patients with Neuroendocrine Tumors of the Pancreas , 2015, The Journal of Nuclear Medicine.

[9]  S. Tretli,et al.  Trends in Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010 , 2015, Neuroendocrinology.

[10]  F. Mottaghy,et al.  Clinical value of ⁶⁸Ga-DOTATATE-PET/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET). , 2015, European journal of radiology.

[11]  A. Carrato,et al.  Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  P. Lapuerta,et al.  37LBA Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial) , 2015 .

[13]  S. Grozinsky-Glasberg,et al.  Clinical features of pancreatic neuroendocrine tumors , 2015, Journal of hepato-biliary-pancreatic sciences.

[14]  C. Chougnet,et al.  Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. , 2015, Endocrine-related cancer.

[15]  F. Kaye,et al.  Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors. , 2015, Journal of the National Cancer Institute.

[16]  G. Capurso,et al.  Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors , 2015, Journal of hepato-biliary-pancreatic sciences.

[17]  I. Steffen,et al.  Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. , 2015, European journal of cancer.

[18]  K. Hess,et al.  Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. , 2015, The Lancet. Oncology.

[19]  Helen X. Chen,et al.  SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127). , 2015 .

[20]  T. Meyer,et al.  Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours. , 2015, Annals of translational medicine.

[21]  A. Grossman,et al.  Carcinoid Heart Disease: From Pathophysiology to Treatment - ‘Something in the Way It Moves' , 2015, Neuroendocrinology.

[22]  K. Delman,et al.  Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach , 2015, Annals of Surgical Oncology.

[23]  R. Hicks,et al.  Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. , 2015, Radiographics : a review publication of the Radiological Society of North America, Inc.

[24]  P. Lapuerta,et al.  Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. , 2015, The Journal of clinical endocrinology and metabolism.

[25]  V. Vilgrain,et al.  Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trial. , 2014, European journal of cancer.

[26]  G. Casazza,et al.  Chromogranin A in Diagnosing and Monitoring Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Large Series from a Single Institution , 2014, Neuroendocrinology.

[27]  D. Coppola,et al.  Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. , 2014, Endocrine-related cancer.

[28]  M. Cuggia,et al.  High Prognostic Value of 18F-FDG PET for Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Long-Term Evaluation , 2014, The Journal of Nuclear Medicine.

[29]  Feng Yang,et al.  Lanreotide in metastatic enteropancreatic neuroendocrine tumors. , 2014, The New England journal of medicine.

[30]  P. Lapuerta,et al.  Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. , 2014, Endocrine-related cancer.

[31]  C. Sette,et al.  Combined therapy with RAD001 e BEZ235 overcomes resistance of PET immortalized cell lines to mTOR inhibition , 2014, Oncotarget.

[32]  Eui Jin Hwang,et al.  Intravoxel Incoherent Motion Diffusion-Weighted Imaging of Pancreatic Neuroendocrine Tumors: Prediction of the Histologic Grade Using Pure Diffusion Coefficient and Tumor Size , 2014, Investigative radiology.

[33]  Y. Iwashita,et al.  Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors , 2014, Journal of hepato-biliary-pancreatic sciences.

[34]  R. Leon-Ferre,et al.  Comparison of Transarterial Liver-Directed Therapies for Low-Grade Metastatic Neuroendocrine Tumors in a Single Institution , 2014, Pancreas.

[35]  A. Scarpa,et al.  Advanced Digestive Neuroendocrine Tumors: Metastatic Pattern Is an Independent Factor Affecting Clinical Outcome , 2014, Pancreas.

[36]  A. Burroughs,et al.  Liver Transplantation for Unresectable Neuroendocrine Tumor Liver Metastases , 2014, Annals of Surgical Oncology.

[37]  M. Falconi,et al.  The Role of Combined 68Ga-DOTANOC and 18FDG PET/CT in the Management of Patients with Pancreatic Neuroendocrine Tumors , 2014, Neuroendocrinology.

[38]  E. Speel,et al.  Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. , 2014, Gastroenterology.

[39]  H. Schild,et al.  Diffusion-weighted imaging with acquisition of three b-values for response evaluation of neuroendocrine liver metastases undergoing selective internal radiotherapy , 2014, European Radiology.

[40]  R. Franco,et al.  Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors , 2014, Endocrine.

[41]  M. Falconi,et al.  Observational study of natural history of small sporadic nonfunctioning pancreatic neuroendocrine tumors. , 2013, The Journal of clinical endocrinology and metabolism.

[42]  Kwhanmien Kim,et al.  Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours , 2013, British Journal of Cancer.

[43]  M. Falconi,et al.  Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases , 2012, The British journal of surgery.

[44]  M. Falconi,et al.  Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study. , 2012, Gastrointestinal endoscopy.

[45]  E. Raymond,et al.  Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies , 2012, Targeted Oncology.

[46]  Jeffrey W. Clark,et al.  Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  A. Scarpa,et al.  Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections. , 2012, European journal of cancer.

[48]  A. Scarpa,et al.  TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. , 2012, Journal of the National Cancer Institute.

[49]  J. Scoazec.  Angiogenesis in Neuroendocrine Tumors: Therapeutic Applications , 2012, Neuroendocrinology.

[50]  F. D. De Braud,et al.  Risk Factors for Disease Progression in Advanced Jejunoileal Neuroendocrine Tumors , 2011, Neuroendocrinology.

[51]  A. Scarpa,et al.  Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  J. Carew,et al.  Mechanisms of mTOR inhibitor resistance in cancer therapy , 2011, Targeted Oncology.

[53]  Michael A. Choti,et al.  DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors , 2011, Science.

[54]  I. Modlin,et al.  The epidemiology of gastroenteropancreatic neuroendocrine tumors. , 2011, Endocrinology and metabolism clinics of North America.

[55]  M. Falconi,et al.  Surgical treatment of pancreatic endocrine tumours in Italy: results of a prospective multicentre study of 262 cases , 2011, Langenbeck's Archives of Surgery.

[56]  M. Falconi,et al.  Role of Resection of the Primary Pancreatic Neuroendocrine Tumour Only in Patients with Unresectable Metastatic Liver Disease: A Systematic Review , 2011, Neuroendocrinology.

[57]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[58]  R. Jensen,et al.  Promising advances in the treatment of malignant pancreatic endocrine tumors. , 2011, The New England journal of medicine.

[59]  B. Niederle,et al.  Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. , 2010, Endocrine-related cancer.

[60]  William Mantovani,et al.  Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients , 2010, Modern Pathology.

[61]  M. Washington,et al.  Pathology Reporting of Neuroendocrine Tumors: Application of the Delphic Consensus Process to the Development of a Minimum Pathology Data Set , 2010, The American journal of surgical pathology.

[62]  C. Croce,et al.  Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  I. Modlin,et al.  Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours , 2009, Alimentary pharmacology & therapeutics.

[64]  C. Schade-Brittinger,et al.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  Ashley B. Grossman,et al.  ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Follow-Up and Documentation , 2009, Neuroendocrinology.

[66]  T. de Baère,et al.  Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. , 2009, Endocrine-related cancer.

[67]  B. Skogseid,et al.  Elevated Plasma Chromogranin A Is the First Indication of Recurrence in Radically Operated Midgut Carcinoid Tumors , 2009, Neuroendocrinology.

[68]  Manal M. Hassan,et al.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  E. Krenning,et al.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  V. Ambrosini,et al.  Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[71]  A. Scarpa,et al.  TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system , 2007, Virchows Archiv.

[72]  A. Scarpa,et al.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system , 2006, Virchows Archiv : an international journal of pathology.

[73]  A. Harris,et al.  Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression , 2004, British Journal of Cancer.

[74]  M. Cremonesi,et al.  Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[75]  P Komminoth,et al.  Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. , 2000, The American journal of pathology.

[76]  T. Visser,et al.  Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients , 1993, European Journal of Nuclear Medicine.

[77]  F. Bösch,et al.  Gastroenteropancreatic Neuroendocrine Tumours , 2019, Gastroenterology For General Surgeons.

[78]  E. Mittra,et al.  177-Lu-Dotatate Significantly Improves Progression-Free Survival in Patients with Midgut Neuroendocrine Tumors : Results of the Phase III NETTER-1 Trial , 2016 .

[79]  R. Salazar,et al.  A randomized open-label phase II study of Everolimus alone or in combination with Pasireotide LAR in advanced, progressive pancreatic neuroendocrine tumors (pNET): COOPERATE-2 trial , 2015 .

[80]  H. Sorbye,et al.  Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[81]  J. Stockman,et al.  Everolimus for Advanced Pancreatic Neuroendocrine Tumors , 2012 .

[82]  F. Bosman,et al.  WHO Classification of Tumours of the Digestive System , 2010 .

[83]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[84]  M. Essen,et al.  et al Treatment with the radiolabeled somatostatinanalog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival Journal of Clinical Oncology : , 2008 .

[85]  D. Ray,et al.  Pathophysiological causes and clinical significance of flushing. , 1993, British journal of hospital medicine.